Hydroxocobalamin dose escalation improves metabolic control in cblC
- 10 October 2009
- journal article
- case report
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 32 (6), 728-731
- https://doi.org/10.1007/s10545-009-1257-y
Abstract
Cobalamin C (cblC), a combined form of methylmalonic acidaemia and hyperhomocysteinaemia, is recognized as the most frequent inborn error of intracellular cobalamin metabolism. This condition can be detected by expanded newborn screening and can have an acute neonatal presentation that is life‐threatening if not suspected and promptly treated. Intramuscular (IM) hydroxocobalamin (OHCbl) is the main treatment for patients with cblC, but formal dosing guidelines do not exist. A clinical improvement and a decrease of plasma methylmalonic acid (MMA) and total homocysteine (tHcy) levels, and an increase in methionine are typically observed after its initiation. It is well recognized that despite treatment, long‐term complications such as developmental delay and progressive visual loss, may still develop. We describe the biochemical response of a 13‐year‐old boy with worsening metabolic parameters despite strict adherence to a conventional treatment regimen. We progressively increased the OHCbl dose from 1 to 20 mg IM per day and observed a dose‐dependent response with an 80% reduction of plasma MMA (25 to 5.14 μmol/L; normal range <0.27 μmol/L), a 55% reduction of tHcy (112 to 50 μmol/L; normal range: 0–13 μmol/L) and a greater than twofold increase in methionine (17 to 36 μmol/L; normal range: 7–47 μmol/L). This suggests that higher OHCbl doses might be required to achieve an optimal biochemical response in cblC patients, but it is unknown whether it may slow or eliminate other complications. Future clinical trials to determine the benefits of higher‐dose OHCbl therapy in patients with cblC and other disorders of intracellular cobalamin metabolism should be planned.Keywords
Funding Information
- National Human Genome Research Institute
- National Institutes of Health
This publication has 24 references indexed in Scilit:
- Spectrum of MMACHC mutations in Italian and Portuguese patients with combined methylmalonic aciduria and homocystinuria, cblC typeMolecular Genetics and Metabolism, 2008
- Combined methylmalonic aciduria and homocystinuria (cblC): Phenotype–genotype correlations and ethnic-specific observationsMolecular Genetics and Metabolism, 2006
- Subacute combined degeneration of the spinal cord in cblC disorder despite treatment with B12Molecular Genetics and Metabolism, 2006
- Safety of Hydroxocobalamin in Healthy Volunteers in a Randomized, Placebo-Controlled StudyClinical Toxicology, 2006
- Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC typeNature Genetics, 2005
- Prenatal and postnatal treatment in cobalamin C defectThe Journal of Pediatrics, 2005
- Cobalamin disorder Cbl‐C presenting with late‐onset thrombotic microangiopathyAmerican Journal of Medical Genetics, 2002
- Optic atrophy in association with cobalamin C (cblC) diseaseOphthalmic Genetics, 2000
- Therapeutic approaches to cobalamin-C methylmalonic acidemia and homocystinuriaThe Journal of Pediatrics, 1988
- Clinical heterogeneity in cobalamin C variant of combined homocystinuria and methylmalonic aciduriaThe Journal of Pediatrics, 1986